MitoDX test for mitochondrial diseases developed by MEDomics

Reported January 18, 2010 AZUSA, Calif. (Ivanhoe Newswire) -- Gwynnie Andrews looks like a healthy 3-year-old. But her body was sending off distress signals from day one.

A droopy eye, fatigue, vomiting and flu-like symptoms were misdiagnosed for nearly two years. Gwynnie's mom had to rush her to the ER several times. "She was in severe metabolic decompensation and possibly several hours away from organ failure and/or sudden death," Gwynnie's mother, Beth Andrews, told Ivanhoe.

Dr. Richard Boles at the University of Southern California diagnosed mitochondrial disease -- genetic defects in the part of the cell that produces energy. The disease can affect multiple organs and produce a variety of symptoms, making it tough to diagnose.

Now a new test is creating a clearer picture of the disease. The test uses saliva or blood samples to look for mutations in any of the 37 mitochondrial genes that are vital for producing energy. Experts say it's 3,000 percent more sensitive than traditional screening methods.

"MitoDX looks at every single base in that mitochondrial genome, and we don't just look at it once -- We look at it thousands of times," Steve Sommer, M.D., Ph.D., founder and president of MEDomics in Azusa, Calif., told Ivanhoe. While there's no cure, early diagnosis can save lives … like Gwynnie's.

"Some children can die as a result of complications," Dr. Sommer said. "After diagnosis and treatment, [Gwynnie] is doing much better. "

Gwynnie gets her blood sugar levels checked daily, snacks frequently and takes supplements that have kept her out of the hospital since her diagnosis. A family who finally has an answer and can now tackle the problem together.

About one in 4,000 children in the U.S. will develop mitochondrial disease by age 10. Dr. Sommer says the turnaround time for the mitochondrial test is six to eight weeks.

Algis (Al) Rajeckas, Ph.D. Joins MEDomics LLC

Steve Sommer, M.D., Ph.D., founder and president of MEDomics LLC is pleased to announce that Algis (Al) Rajeckas has joined MEDomics as West Coast Director of Mrketing. Dr. Rajeckas brings over 25 years experience with clinical diagnostics, biotech and life sciences companies.

Prior to joining MEDomics, Dr. Rajeckas has been a marketing consultant for clinical diagnostics and life sciences companies and has served as Vice President of the Life Sciences and BioPharma Division at DevicePharm. He also successfully introduced new esoteric clinical diagnostics tests in the hospital market while at Quest Diagnostics, the largest commercial reference laboratory.

Other experience includes product marketing at Celera Genomics, ICN Biomedicals and DuPont Biotechnology Systems (NEN). Dr. Rajeckas earned a Ph.D. in synthetic organic chemistry at the Massachusetts Institute of Technology and a B.S. in Chemistry from Trinity College, Hartford.
*****